<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151876</url>
  </required_header>
  <id_info>
    <org_study_id>ChiCGB-DLBCL</org_study_id>
    <nct_id>NCT03151876</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB
      regimen( chidamide, cladribine, gemcitabine and busulfan).

      Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells),
      which may cause cancer cells to die.

      Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may
      cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by
      not allowing these cells to repair the DNA damage caused by busulfan.

      Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA,
      such as cladribine, gemcitabine, busulfan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will be enrolled in a group
      of at least 3 participants to begin receiving the study drugs.

      The dose of the study drugs you receive will depend on when you enrolled in this study. If no
      intolerable side effects occur in your group, researchers will continue to enroll
      participants at the next dose level until either the vorinostat reaches the dose level
      currently used alone without stem cell transplant, or the highest tolerable dose of this drug
      is found. The dose that you receive will remain the same throughout this study.

      You will be admitted to the hospital on Day -6.

      Study Drug Administration (for all patients):

      In stem cell transplant, the days before you receive your stem cells are called minus days.
      The day you receive the stem cells is called Day 0. The days after you receive your stem
      cells are called plus days.

      On Day -7, -4, 0, +3 , you will take chidamide by mouth.

      On Days -6, -5, -4, -3, and -2 you will receive cladribine by vein over 1/2 hours.

      On Day -6, -2, you will receive gemcitabine by vein over 3 1/2 - 4 1/2 hours.

      On Days -6, -5, -4, and -3, you will receive busulfan by vein over 3 hours.

      On Day -1, you will rest.

      On Day 0, you will receive your stem cells by vein over about 30-60 minutes.

      As part of standard care, you will receive G-CSF (filgrastim) as an injection just under your
      skin twice a day starting on Day +5 until your blood cell levels return to normal.

      Study Tests:

      On Day -1, you will have an electrocardiogram (ECG) to check your heart function.

      About 30-100 days after the transplant, you will have lung function tests.

      About 100 days after the transplant:

      Blood (about 4 teaspoons) will be drawn for routine tests. If the doctor thinks it is needed,
      you may have a bone marrow aspiration and biopsy to check the status of the disease.

      You will have a PET/CT scan of your whole body to check the status of the disease.

      Length of Study:

      As part of standard care, you will remain in the hospital for about 3-4 weeks after the
      transplant. After you are released from the hospital, you will continue as an outpatient for
      infections and transplant-related complications.

      You will be taken off study about 100 days after the transplant. You may be taken off study
      early if the disease gets worse, if intolerable side effects occur, or if you are unable to
      follow study directions.

      This is an investigational study. Chidamide, gemcitabine, busulfan, melphalan, and rituximab
      are all FDA approved and commercially available. The use of these study drugs in combination
      is investigational.

      Up to 93 patients will take part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ChiCGB</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>3 month after autologous hematopoietic stem cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ChiCGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: ChiCGB
Chidamide administered orally on D-7, -4, 0,+3
Cladribine administered at 10mg on D-6 to D-2
Gemcitabine administered at 2500 mg/m2 on days -6 and -2.
Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.
Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.
Interventions:
Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30 mg oral twice weekly for 2 weeks</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>6 mg/m2 intravenously daily for 5 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>2500 mg/m2 intravenously twice weekly for 1 week</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>3.2 mg/kg intravenously daily for 4 days</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>autologous hematopoietic stem cells infusion after ChiCGB chemotherapy</description>
    <arm_group_label>ChiCGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with primary refractory or recurrent diffuse large B cell lymphoma that do
             not qualify for treatment protocols of higher priority.

          2. Relapsed patients should respond to 2nd or 3rd line salvage chemotherapy and attain at
             least PR before recruitment.

          3. Adequate renal function, as defined by estimated serum creatinine clearance &gt;/=50
             ml/min and/or serum creatinine &lt;/= 1.8 mg/dL.

        6. Adequate hepatic function, as defined by serum glutamate oxaloacetate transaminase
        (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) &lt;/= 3 x upper limit of normal;
        serum bilirubin and alkaline phosphatase &lt;/= 2 x upper limit of normal.

        7. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced
        vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) &gt;/= 50% of
        expected corrected for hemoglobin.

        8. Adequate cardiac function with left ventricular ejection fraction &gt;/= 50%. No
        uncontrolled arrhythmias or symptomatic cardiac disease.

        9. Performance status 0-1. 10. Negative Beta diffusing capacity of lung for carbon monoxide
        (HCG) text in a woman with child-bearing potential, defined as not post-menopausal for 12
        months or no previous surgical sterilization

        Exclusion Criteria:

          1. Central nervous system lymphoma

          2. Patients relapsed after ASCT

          3. Bone marrow was involved by lymphoma

          4. Patients with active hepatitis B or C(HBV DNA &gt;/=10,000 copies/mL).

          5. Active infection requiring parenteral antibiotics

          6. HIV infection, unless the patient is receiving effective antiretroviral therapy with
             undetectable viral load and normal cluster of differentiation 4 (CD4) counts

          7. Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic
             hepatitis C or positive hepatitis C serology.

          8. Patients with a cQT longer than 500 ms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Ji, MD</last_name>
    <phone>86-28-85422370</phone>
    <email>JieJi@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Liu, MD</last_name>
    <phone>86-28-85422373</phone>
    <email>liuting@scu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Xie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking university third hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoyan Ke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lin Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dabing Qin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Lanzhou military command</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hai Bai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinhua Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Cao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu province hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rui jin hospital Shanghai jiao tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiong Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tong Ren Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ligen L i u, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shan Xi Da Yi Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Gong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Ji, MD</last_name>
      <phone>86-28-85422370</phone>
      <email>jieji@scu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Southwest Medical University</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>646000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoming Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blood diseases hospital, Chinese academy of medica</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjing</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lvgui Qiu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Xinjiang medical Universtiy</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Jiang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kunming General Hospital of Chengdu Military Area</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanbin Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Jie Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>electronic case report form (eCRF)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

